16. クロウ・深瀬症候群 Crow-Fukase syndrome Clinical trials / Disease details


臨床試験数 : 13 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 75

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02921893
(ClinicalTrials.gov)
October 31, 201626/9/2016Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeIxazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromePlasmacytoma;POEMS SyndromeDrug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Lenalidomide;Other: Questionnaire AdministrationMayo ClinicNational Cancer Institute (NCI)Active, not recruiting18 YearsN/AAll21Early Phase 1United States
2NCT02193698
(ClinicalTrials.gov)
July 201416/7/2014Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome TrialSingle Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) SyndromePOEMS SyndromeDrug: Lenalidomide+DexamethasoneChiba UniversityNULLCompleted20 YearsN/ABoth5Phase 2Japan
3NCT01816620
(ClinicalTrials.gov)
March 201414/3/2013Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS SyndromeAn Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS SyndromePOEMS SyndromeDrug: Lenalidomide, DexamethasonePeking Union Medical College HospitalCelgene CorporationCompleted18 YearsN/AAll41Phase 2China
4NCT01639898
(ClinicalTrials.gov)
July 20125/7/2012POEMS Syndrome Treatment With LenalidomidePhase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.POEMS SyndromeDrug: Lenalidomide and dexamethasoneUniversity Hospital, LimogesMinistry of Health, France;Celgene CorporationCompleted18 YearsN/AAll51Phase 2France
5EUCTR2008-003202-33-IT
(EUCTR)
15/09/200917/11/2009Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 POEMS SYNDROME
MedDRA version: 9.1;Level: SOC;Classification code 10029205
Trade Name: REVLIMID*21CPS 25MG
INN or Proposed INN: Lenalidomide
ISTITUTO CLINICO HUMANITASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
6NCT00971685
(ClinicalTrials.gov)
July 20093/9/2009The Treatment of Lenalidomide in Patients With POEMS SyndromeEvaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS SyndromePOEMS SyndromeDrug: Lenalidomide and dexamethasoneIstituto Clinico HumanitasNULLRecruiting18 YearsN/ABoth16Phase 2Italy